Andrew Bzowyckyj, PharmD, explains how the CKM framework turns albuminuria, ejection fraction, and inflammation into patient-specific risk stratification.
Andrew Bzowyckyj, PharmD, BCPS, CDCES, FADCES, FAPhA, FCCP
Advertisement
Andrew Bzowyckyj, PharmD, BCPS, CDCES, FADCES, FAPhA, FCCP, is senior scientific director and learning consultant at the National Kidney Foundation.
Articles by Andrew Bzowyckyj, PharmD, BCPS, CDCES, FADCES, FAPhA, FCCP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
2
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
3
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
4
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
5